Furthermore, since the identified LDL-binding–defective PCSK9 mutations are associated with FH, these data lend support to the notion that LDL association exerts an inhibitory effect on the ability of PCSK9 to mediate hepatic LDLR degradation in humans. Here, PCSK9 is linked to familial hyperaldosteronism.